Pharmaceuticals - Indian - Formulations
Particulars (in ₹ Cr.) | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
---|---|---|---|---|---|
Total Revenue | 42.73 | 44.01 | 78.50 | 66.10 | 87.30 |
Total Expenses | 44.61 | 62.31 | 93.22 | 86.46 | 102.62 |
Profit Before Tax | -1.88 | -18.29 | -14.72 | -20.36 | -15.32 |
Profit After Tax | -1.88 | -19.36 | -16.91 | -19.46 | -15.14 |
Operating Profit after Depreciation | -1.79 | -16.17 | -7.77 | -8.89 | -2.36 |
Particulars (in ₹ Cr.) | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
---|---|---|---|---|---|
Fixed Assets | 35 | 37.05 | 44.90 | 48.61 | 52.61 |
Total Non Current Assets | 35.22 | 71 | 89.62 | 101.12 | 70.22 |
Total Current Assets | 36.10 | 48.47 | 48.74 | 77.18 | 122.48 |
TOTAL ASSETS | 71.31 | 119.47 | 138.36 | 178.31 | 192.71 |
Total Shareholder's Fund | 51.11 | 19.06 | 37.93 | 42.67 | 57.75 |
Particulars (in ₹ Cr.) | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
---|---|---|---|---|---|
Net Cash from Operating Activities | -34.31 | -1.79 | -7.05 | -0.95 | 0.91 |
Net Cash used in Investing Activities | 32.77 | 15.36 | 37.97 | -5.42 | -0.36 |
Net Cash used in Financing Activities | 7.30 | -13.81 | -30.63 | 6.31 | -0.61 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Total Revenue | 155.99 | 118.62 | 86.84 | 71.97 | 42.73 |
Total Expenses | 148.64 | 107.01 | 79.47 | 66.14 | 44.61 |
Profit Before Tax | 7.35 | 11.62 | 5.22 | 5.83 | -1.88 |
Profit After Tax | 7.35 | 11.34 | 5.22 | 5.83 | -1.88 |
Operating Profit after Depreciation | 9.64 | 13.65 | 8.17 | 6.57 | -1.78 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Fixed Assets | 41.98 | 41.73 | 38.85 | 35.97 | 34.97 |
Total Non Current Assets | 53.21 | 42.27 | 39.26 | 36.80 | 35.18 |
Total Current Assets | 94.47 | 87.31 | 50.88 | 49.67 | 35.88 |
TOTAL ASSETS | 147.68 | 129.58 | 90.14 | 86.47 | 71.06 |
Total Shareholder's Fund | 80.84 | 73.45 | 61.96 | 56.77 | 50.95 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Net Cash from Operating Activities | 9.48 | 4.95 | 9.73 | -13.61 | -34.27 |
Net Cash used in Investing Activities | -15.05 | -7.49 | -6.54 | -5.35 | 32.78 |
Net Cash used in Financing Activities | -0.85 | 10.18 | -4.81 | 12.28 | 7.27 |
Particulars (in ₹ Cr.) | 2019-09 | 2019-06 | 2018-09 | 2018-06 |
---|---|---|---|---|
Total Revenue | 11.57 | 6.85 | 8.84 | - |
Total Expenses | 11.94 | 9.71 | 8.66 | - |
Profit Before Tax | -0.54 | -3.71 | -1.22 | - |
Profit After Tax | -0.59 | -2.13 | -1.28 | -3.52 |
Operating Profit after Depreciation | 0.22 | -2.56 | 0.15 | - |
Particulars (in ₹ Cr.) | 2024-12 | 2024-09 | 2024-06 | 2024-03 | 2023-12 |
---|---|---|---|---|---|
Total Revenue | 33.19 | 40.32 | 33.29 | 41.40 | 28.44 |
Total Expenses | 30.12 | 36.53 | 32.08 | 38.51 | 30.52 |
Profit Before Tax | 0.95 | 2.61 | -0.72 | 1.46 | -2.95 |
Profit After Tax | 0.95 | 2.62 | -0.72 | 1.46 | -2.94 |
Operating Profit after Depreciation | 3.26 | 4.81 | 1.72 | 3.41 | -1.10 |
Company | Price | Market Cap (in ₹ Cr) |
---|---|---|
Bafna Pharmaceuticals Ltd | ₹75.10 | ₹177.66 |
Sun Pharmaceuticals Industries Ltd | ₹1,699.75 | ₹4,07,826.96 |
Divis Laboratories Ltd | ₹5,949.15 | ₹1,57,931.24 |
Cipla Ltd | ₹1,452.70 | ₹1,17,322.09 |
Torrent Pharmaceuticals Ltd | ₹3,104.95 | ₹1,05,080.90 |
Mankind Pharma Ltd | ₹2,451.35 | ₹1,01,134.59 |
On 6 February 2025
28 Jan 2025, 05:34 pm
On 11 November 2024
04 Nov 2024, 06:39 pm
On 25 September 2024
05 Sep 2024, 10:29 am
On 25 September 2024
04 Sep 2024, 05:49 pm
On 13 August 2024
10 Aug 2024, 01:56 pm